Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2681 - 2688 of 11540 results
Health Law Diagnosed — Hot Topics in FDA Regulation and Enforcement
May 12, 2021| Podcast| Viewpoint
Travel Alert – Update on U.S. Travel Bans
May 12, 2021| Alert| Viewpoint
Massachusetts Public Health Council Approves Amendments to Clinic Licensure Regulations
May 11, 2021| Blog| Viewpoint
The American Families Plan & A Call for Drug Pricing Legislation
May 10, 2021| Blog| Viewpoint
FDA Ups the Ante and Sends First Notice of Noncompliance for Failure to Submit Clinical Trial Results
May 6, 2021| Blog| Viewpoint
News & Press Releases
Mintz Announces Partnership with Lineal’s Amplify Technology Suite
November 19, 2024
Mintz has partnered with Lineal, a leader in legal technology and data review solutions to assist with client services delivery. The collaboration brings Lineal’s Amplify Suite—an advanced RelativityOne integration—into Mintz’s practice to enhance early data assessment (EDA), streamline modern data review, and manage strategic decision calls.
Mintz Advises Aspen Aerogels on $98M Follow-on Offering
November 19, 2024
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Mintz Advises Charlesbank Capital Partners on Strategic Investment with IMPLAN Group
November 18, 2024
Mintz advised Charlesbank Capital Partners (“Charlesbank”), a middle-market private equity firm with more than $22 billion in total assets, on a strategic investment with IMPLAN Group LLC (“IMPLAN”), a leading provider of economic impact data and analytical software.